You are here:

Release of Indirect Comparison Checklist to Industry

The New Drugs Committee (NDC) Indirect Comparison and Mixed Treatment Comparisons Checklist forms part of the paperwork that is provided to NDC and SMC members in advance of meetings. The checklist is a working document that is used by the assessment team to assess the quality and validity of the indirect comparison; confirming the type of analysis, reviewing study selection and methodology and identifying the areas where statistical expertise is required.

The Indirect Comparison and Mixed Treatment Comparisons Checklist is provided to the manufacturer, in confidence, for information purposes only and will be released on the same day as the SMC advice is provided to the manufacturer. Publication of the checklist, or parts thereof, is prohibited.

In accordance with the Data Protection Act 1998 and any other applicable data protection legislation, all personal information has been removed from the checklist prior to release to the manufacturer.